UK markets closed

Aerie Pharmaceuticals, Inc. (AERI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.91+0.23 (+2.38%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 5460.96M
Enterprise value 3434.01M
Trailing P/E N/A
Forward P/E 1-4.27
PEG ratio (5-yr expected) 10.05
Price/sales (ttm)5.65
Price/book (mrq)5.13
Enterprise value/revenue 35.32
Enterprise value/EBITDA 6-2.85

Trading information

Stock price history

Beta (5Y monthly) 0.82
52-week change 3-55.92%
S&P500 52-week change 314.01%
52-week high 326.26
52-week low 39.01
50-day moving average 311.32
200-day moving average 313.22

Share statistics

Avg vol (3-month) 3742.38k
Avg vol (10-day) 31.06M
Shares outstanding 546.51M
Float 45.5M
% held by insiders 12.08%
% held by institutions 1131.45%
Shares short (29 Sep 2020) 48.76M
Short ratio (29 Sep 2020) 412.67
Short % of float (29 Sep 2020) 425.97%
Short % of shares outstanding (29 Sep 2020) 418.83%
Shares short (prior month 30 Aug 2020) 48.36M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2019
Most-recent quarter (mrq)29 Jun 2020

Profitability

Profit margin -247.36%
Operating margin (ttm)-220.36%

Management effectiveness

Return on assets (ttm)-36.28%
Return on equity (ttm)-164.34%

Income statement

Revenue (ttm)81.58M
Revenue per share (ttm)1.79
Quarterly revenue growth (yoy)13.90%
Gross profit (ttm)42.29M
EBITDA -152.21M
Net income avi to common (ttm)-201.78M
Diluted EPS (ttm)-4.42
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)241.92M
Total cash per share (mrq)5.2
Total debt (mrq)214.97M
Total debt/equity (mrq)239.36
Current ratio (mrq)3.73
Book value per share (mrq)1.93

Cash flow statement

Operating cash flow (ttm)-130.01M
Levered free cash flow (ttm)-74.29M